ESH MM 2018 | Exploring treatment options against different Waldenström’s mutations
Steven Treon
• 5 Oct 2018
BTK inhibitors like ibrutinib exhibit high response rates in both the frontline and relapsed settings for Waldenström’s macroglobulinemia (WM), but that may not suffice, suggests Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA. Recent genomic advancements may offer insight into the management of patients with different WM mutations, such as MYD88 and CXCR4. Dr Treon also calls for patience on the clinicians’ part, since response rates may be much slower for less common mutations. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
